NCT02278783 - Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

January 31, 2017

Conditions

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer

Interventions

DRUG

regorafenib

Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City